New hope for rare kidney disease: experimental drug NM8074 enters human trials
NCT ID NCT05647811
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug called NM8074 in 18 adults with C3 Glomerulopathy (C3G), a rare kidney disease. The drug is given by IV over several weeks to see if it is safe and can reduce protein in the urine, a sign of kidney damage. Researchers will also check how the body responds to the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NM8074
- What this could lead to
- If successful, this could point toward a new treatment option for C3 Glomerulopathy, a rare kidney disease with limited therapies.
- What could go wrong
- This is a very early, small trial (18 people) testing safety and dosing. It may not show clear benefit, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to stop kidney disease from coming back after transplant
- New drug shows promise for controlling rare kidney disorders
- New drug fabhalta under Real-World watch in korea for rare blood and kidney diseases
- Hope for rare kidney patients: new drug shows promise in phase 3 trial
- New study to map Real-World use of iptacopan in rare kidney disease
- New hope for rare kidney patients: Long-Term drug trial shows promise